Literature DB >> 33718430

In Spite of Curative Radical Pulmonary Procedures, Lesser Pulmonary Resection Shows More Favorable Prognosis in Surgically Treated NSCLC With Synchronous Isolated Cranial Oligometastases.

Erkan Kaba1, Eyüp Halit Yardımcı1, Jahnavi Kakuturu2, Alper Toker2.   

Abstract

Oligometastatic disease in lung cancer is not a rare condition as previously thought. Among 812 non-small cell lung cancer patients treated surgically with lung resection between October 2011 and October 2018 at the Department of Thoracic Surgery, Florence Nightingale Hospitals, Turkey, 28 patients (3.4%) had synchronous cranial metastases. We analyzed synchronous isolated cranial metastases patients treated by locally ablative treatments (surgery, radiotherapy, or both). Metastases existing at the diagnosis of primary cancer were considered as synchronous, and their treatment was performed before (at least 1 month) or after (for maximum 1 month) surgery of the primary lung lesion. Prognostic factors affecting survival are evaluated retrospectively to identify clinical factors predicting survival in an effort to better select patients for surgery. Patients having T1-T2 primary lung tumors, no mediastinal lymph node metastasis, receiving minor anatomical lung resection, receiving neoadjuvant chemotherapy, having single cranial metastasis, and receiving surgical cranial metastasectomy were found to have better survival. According to tumor histology, having adenocarcinoma, and not having lymphovascular or visceral pleura invasion correlated with better survival. Average survival time was 52.1 months and median survival was 32 months. The last mortality during the follow-up was at 24 months; cumulative survival was 48.3% at that time. Our study was designed to define the criteria for patients with oligometastatic disease who may benefit from lung resection.
Copyright © 2021 Kaba, Yardımcı, Kakuturu and Toker.

Entities:  

Keywords:  cranial; lung cancer; multimodality treatment; non-small cell; oligometastases; pulmonary resection; radiotherapy; synchronous

Year:  2021        PMID: 33718430      PMCID: PMC7947805          DOI: 10.3389/fsurg.2021.645870

Source DB:  PubMed          Journal:  Front Surg        ISSN: 2296-875X


  28 in total

Review 1.  PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer.

Authors:  Mia Schmidt-Hansen; David R Baldwin; Elise Hasler; Javier Zamora; Víctor Abraira; Marta Roqué I Figuls
Journal:  Cochrane Database Syst Rev       Date:  2014-11-13

2.  Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.

Authors:  Ravi B Parikh; Angel M Cronin; David E Kozono; Geoffrey R Oxnard; Raymond H Mak; David M Jackman; Peter C Lo; Elizabeth H Baldini; Bruce E Johnson; Aileen B Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-24       Impact factor: 7.038

3.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

Review 4.  Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.

Authors:  Francesco Grossi; Kaoru Kubota; Federico Cappuzzo; Filippo de Marinis; Cesare Gridelli; Marianna Aita; Jean-Yves Douillard
Journal:  Oncologist       Date:  2010-10-07

5.  Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer?

Authors:  Pierre Mordant; Alex Arame; Florence De Dominicis; Ciprian Pricopi; Christophe Foucault; Antoine Dujon; Françoise Le Pimpec-Barthes; Marc Riquet
Journal:  Eur J Cardiothorac Surg       Date:  2012-01-04       Impact factor: 4.191

6.  Prognostic factors of oligometastatic non-small-cell lung cancer following radical therapy: a multicentre analysis.

Authors:  Isabelle Opitz; Miriam Patella; Loic Payrard; Jean Yannis Perentes; Rolf Inderbitzi; Hans Gelpke; Sandra Schulte; Maja Diezi; Michel Gonzalez; Thorsten Krueger; Walter Weder
Journal:  Eur J Cardiothorac Surg       Date:  2020-06-01       Impact factor: 4.191

7.  A prospective study of surgical procedures for patients with oligometastatic non-small cell lung cancer.

Authors:  Chiaki Endo; Tohru Hasumi; Yuji Matsumura; Nobuyuki Sato; Hiroyuki Deguchi; Hiroyuki Oizumi; Motoyasu Sagawa; Takao Tsushima; Satomi Takahashi; Jotaro Shibuya; Masahide Hirose; Takashi Kondo
Journal:  Ann Thorac Surg       Date:  2014-04-18       Impact factor: 4.330

8.  Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.

Authors:  Gwendolyn H M J Griffioen; Daniel Toguri; Max Dahele; Andrew Warner; Patricia F de Haan; George B Rodrigues; Ben J Slotman; Brian P Yaremko; Suresh Senan; David A Palma
Journal:  Lung Cancer       Date:  2013-08-06       Impact factor: 5.705

9.  Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007.

Authors:  Sarah Walters; Camille Maringe; Michel P Coleman; Michael D Peake; John Butler; Nicholas Young; Stefan Bergström; Louise Hanna; Erik Jakobsen; Karl Kölbeck; Stein Sundstrøm; Gerda Engholm; Anna Gavin; Marianne L Gjerstorff; Juanita Hatcher; Tom Børge Johannesen; Karen M Linklater; Colleen E McGahan; John Steward; Elizabeth Tracey; Donna Turner; Michael A Richards; Bernard Rachet
Journal:  Thorax       Date:  2013-02-11       Impact factor: 9.139

10.  Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs.

Authors:  Yves A Lussier; Nikolai N Khodarev; Kelly Regan; Kimberly Corbin; Haiquan Li; Sabha Ganai; Sajid A Khan; Jennifer L Gnerlich; Jennifer Gnerlich; Thomas E Darga; Hanli Fan; Oleksiy Karpenko; Philip B Paty; Mitchell C Posner; Steven J Chmura; Samuel Hellman; Mark K Ferguson; Ralph R Weichselbaum
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more
  2 in total

1.  Editorial: Bench Research Behind Lung Cancer Surgery.

Authors:  Luca Bertolaccini; Lorenzo Spaggiari; Jessica Cusato
Journal:  Front Surg       Date:  2022-06-21

2.  Prognostic value of thoracic tumor staging and volume parameters in non-small cell lung cancer patients with synchronous solitary bone metastasis.

Authors:  Kan Deng; Shuping Li; Jian Zhang; Xiande Ye; Kai Yao; Ying Li; Jianru Xiao
Journal:  J Thorac Dis       Date:  2022-04       Impact factor: 3.005

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.